Figure 2: Serelaxin Does Not Reduce Left Ventricular Hypertrophy or Remodeling in the Angiotensin II/L-NG-Nitroarginine Methyl Ester Model

Cardiac ultrasound was performed followed by organ harvest and histology in the Acute:on-treatment (day 9) and Chronic:post-treatment (day 28) groups in angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME)–treated mice. (A) Heart and left ventricular (LV) mass normalized to tibia length. (B) Cardiac dimensions and function as measured by echocardiography. (C) Representative and summary data of cardiac myocyte cross-sectional area from hematoxylin and eosin–stained LV sections (scale bar represents 0.3 μm) and of interstitial fibrosis from picrosirius red–stained LV sections (scale bar represents 1 μm). n = 6 (day 9) or 5 (day 28) per treatment. Connected single bars over days 9 and 28 indicate analysis of main effects of time factor for vehicle and serelaxin in combination. *p < 0.01 and †p = 0.024, day 9 versus day 28; ‡p = 0.027 for main effects of treatment factor serelaxin versus vehicle. Two-factor analysis of variance with Tukey post hoc test.



Elsevier user license